Century Therapeutics, Inc.

centurytx.com

What Do They Do?

Develops ready-made cell therapies for autoimmune diseases, including diabetes, and cancer.

How Do They Make Money?

Partners can pay upfront fees, reimburse research costs, and make option and milestone payments or pay royalties under collaboration and licensing agreements. Research work is paid as it is provided, while license fees and milestone payments are tied to exercising options or reaching milestones.

FY2025 revenue

Who Are Their Customers?

Bristol Myers Squibb works directly with Century on research and development of cell programs, with the option to license candidates for later development and commercialization.

Do Revenues Turn Into Profits?

No. It lost $9.6M in FY2025.

Operating income, FY2025

−16% of revenue

▼ −87% (Loss) vs FY2024 (−$138.1M, −2096%)

Net income, FY2025

−9% of revenue

▼ −92% (Loss) vs FY2024 (−$126.6M, −1921%)

Free cash flow, FY2025

−96% of revenue

▼ −5% (Loss) vs FY2024 (−$110.3M, −1674%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Net income: ▲ +6% (Loss); vs −$32.5M in Q2 FY2025

Broader disease focus The older report centered on cell therapies for solid tumors and blood cancers; the latest also develops therapies for autoimmune diseases, including diabetes, with a beta-islet replacement program.

Who Do They Compete With?

Competes with AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Merck, Novartis, Pfizer, Roche, Adicet Bio, Allogene Therapeutics, Artiva Biotherapeutics, Caribou Biosciences, Fate Therapeutics, Nkarta Therapeutics, Cabaletta Bio, Cartesian Therapeutics, Kyverna Therapeutics, Vertex Pharmaceuticals, Sana Biotechnology, CRISPR Therapeutics, and CellTrans

Comments